Trial Profile
A Dose-Escalation and Dose Expansion Phase I Clinical Study of HQP1351 in Patients with Tyrosine Kinase Inhibitor (TKI)-Refractory Chronic Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Olverembatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus First in man; Therapeutic Use
- 13 Dec 2022 Results of five-year follow-up on safety and efficacy of olverembatinib, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 According to an Ascentage Pharma media release, results from this study were presented at ASH 2021.